Infections are one of the major drivers of mortality among solid organ transplant recipients (SOTR) and bacteria are the most frequent cause of infections after solid organ transplantation, especially in early post-transplant stages. In recent years, a progressive growth in the prevalence of colonization because of multidrug-resistant (MDR) strains has been observed in this population, ranging from approximately 10% to 30% according to the local epidemiological scenario, the type of transplanted organ, and the bacterial species and mechanism of resistance [1]. On the basis of the most widely accepted definition, the term MDR strains commonly indicates lack of susceptibility to one or more agents in three or more antimicrobial categories and includes methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), third-generation cephalosporin-resistant Enterobacterales (3GCephRE), carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRA). Major risk factors for acquiring colonization with MDR strains among SOTR are prolonged hospitalization, intensive care unit (ICU) admission, and multiple antibiotic therapies usually required for relapsing bacterial infections because of the severe immunosuppressed status and multiple comorbidities [2,3]. Implementing preventive strategies requires a complex approach targeting both the recipient in the pre- and post-transplantation period and the donor where there is an increased risk of donor-acquired new colonization with MDR strains as in the majority of cases the donor is admitted to the ICU [4].